Search research articles
Contact Us
Filters
Showing results (11-20 of 73) with videos related to
Page
of 8
Sort By:
Seminars in Oncology
|
August 1, 1993
Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update
C A Linker, L E Damon, C A Ries, et al.
Progress in Clinical and Biological Research
|
January 1, 1994
High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma
H S Rugo, L E Damon, C A Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1997
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency
G A Smith, L E Damon, H S Rugo, et al.
Bone Marrow Transplantation
|
November 25, 1998
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report
C A Linker, C A Ries, L E Damon, et al.
Endoscopy
|
October 1, 1996
The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation
J P Terdiman, C A Linker, C A Ries, et al.
The Journal of Clinical Investigation
|
March 1, 1992
Local cytokine production in a murine model of Escherichia coli pyelonephritis
H S Rugo, P O'Hanley, A G Bishop, et al.
Ophthalmology
|
December 26, 2001
Ocular manifestations of leukemia: leukemic infiltration versus infectious process
K B Gordon, H S Rugo, J L Duncan, et al.
ESMO Open
|
January 4, 2025
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting
H S Rugo, R M Layman, F Lynce, et al.
ESMO Open
|
June 18, 2025
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting
H S Rugo, R M Layman, F Lynce, et al.
ESMO Open
|
September 2, 2025
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
H S Rugo, R M Layman, F Lynce, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 73) with videos related to
Sort By:
Page
of 8
Seminars in Oncology
|
August 1, 1993
Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update
C A Linker, L E Damon, C A Ries, et al.
Progress in Clinical and Biological Research
|
January 1, 1994
High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma
H S Rugo, L E Damon, C A Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1997
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency
G A Smith, L E Damon, H S Rugo, et al.
Bone Marrow Transplantation
|
November 25, 1998
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report
C A Linker, C A Ries, L E Damon, et al.
Endoscopy
|
October 1, 1996
The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation
J P Terdiman, C A Linker, C A Ries, et al.
The Journal of Clinical Investigation
|
March 1, 1992
Local cytokine production in a murine model of Escherichia coli pyelonephritis
H S Rugo, P O'Hanley, A G Bishop, et al.
Ophthalmology
|
December 26, 2001
Ocular manifestations of leukemia: leukemic infiltration versus infectious process
K B Gordon, H S Rugo, J L Duncan, et al.
ESMO Open
|
January 4, 2025
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting
H S Rugo, R M Layman, F Lynce, et al.
ESMO Open
|
June 18, 2025
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting
H S Rugo, R M Layman, F Lynce, et al.
ESMO Open
|
September 2, 2025
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
H S Rugo, R M Layman, F Lynce, et al.
Page
of 8